As CBA treatment was associated with lowerlevels of CRP, it may result in a lower rate of ERAF, however, the STOP AF trialindicated that ERAF was a common finding, regardless of the application of CBA[42]. The gene discussed is CRP; the disease is atrial fibrillation.